Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1969]

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline...

Dr Lorenz Trümper - Georg August University, Göttingen, Germany

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )

AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed...

Prof Marion Subklewe - University of Munich, Munich, Germany

$AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )$

KRd versus VRd in patients with newly diagnosed multiple myeloma

Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA

KRd versus VRd in patients with newly diagnosed multiple myeloma ( Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA )

Researchers identify mutation that causes resistance to venetoclax in CLL...

Dr Piers Blombery - University of Melbourne, Melbourne, Australia

Researchers identify mutation that causes resistance to venetoclax in CLL patients ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )

Daratumumab increases PFS in patients with transplant-ineligible multiple...

Prof Thierry Facon - Hôpital Claude Huriez, Lille, France

Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for...

Dr Tait Shanafelt - Standford University, Stanford, USA

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )

Resistance mechanisms to venetoclax in patients with progressive CLL

Dr Piers Blombery - University of Melbourne, Melbourne, Australia

Resistance mechanisms to venetoclax in patients with progressive CLL ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy

Dr Alok Khorana - Cleveland Clinic, Cleveland, USA

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy ( Dr Alok Khorana - Cleveland Clinic, Cleveland, USA )

Ibrutinib-based therapy superior for younger patients with previously untreated...

Dr Tait Shanafelt - Stanford University, Stanford, USA

Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care ( Dr Tait Shanafelt - Stanford University, Stanford, USA )

Daratumumab found to increase PFS in patients with transplant-ineligible newly...

Prof Thierry Facon - Hôpital Claude Huriez, Lille, France

Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )

Patient treatment preferences in relapsed/refractory multiple myeloma

Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos

$Patient treatment preferences in relapsed/refractory multiple myeloma ( Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos )$

Landscape change with oral proteasome maintenance in multiple myeloma patients

Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar...

Landscape change with oral proteasome maintenance in multiple myeloma patients ( Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lonial )

More from ecancer